Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.62 |
| ▸ | HTR6 | P50406 | 8/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14286783 | 0.89 | ALOX5 (0.55) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL838015 | 0.83 | HTR6 (0.64) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL838017 | 0.83 | HTR6 (0.64) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL26193435 | 0.80 | HTR6 (0.50) | ALOX5PTGS2HTR6 | |
| SCHEMBL9054387 | 0.79 | HTR6 (0.67) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL29169606 | 0.78 | HTR6 (0.67) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL946516 | 0.78 | HTR6 (0.74) | ALOX5PTGS2HTR6L3MBTL1ALK | |
| SCHEMBL24719041 | 0.77 | ADAM17 (0.53) | KDM4E | |
| SCHEMBL22521341 | 0.77 | ADAM17 (0.53) | KDM4E | |
| SCHEMBL27153025 | 0.77 | ADAM17 (0.53) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7439228-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | ALOX5 1789/4885PTGS2 4220/4885HTR6 4337/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | ALOX5 285/4885PTGS2 1418/4885HTR6 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.